Dexcom (DXCM) Cash & Equivalents (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash & Equivalents data on file, last reported at $1.1 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.1 billion, up 23.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 23.57% YoY), and the FY2025 annual result was $392.8 million, up 192.7% from the prior year.
• Cash & Equivalents advanced to $1.1 billion in Q1 2026 per DXCM's latest filing, from $392.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.4 billion in Q3 2025 and troughed at $134.2 million in Q4 2024.
• A 5-year average of $750.9 million and a median of $698.1 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 76.3% in 2024, then jumped 192.7% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $642.3 million in 2022, then slipped by 11.83% to $566.3 million in 2023, then tumbled by 76.3% to $134.2 million in 2024, then jumped by 192.7% to $392.8 million in 2025, then jumped by 184.67% to $1.1 billion in 2026.
• Business Quant data shows DXCM's Cash & Equivalents at $1.1 billion in Q1 2026, $392.8 million in Q4 2025, and $1.4 billion in Q3 2025.